Akers Biosciences, Inc. Starts Clinical Trials For PIFA PLUSS Chlamydia Assay

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

THOROFARE, N.J., April 30, 2014 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (Nasdaq:AKER) (LSE:AKR) (the “Company” or “ABI”), a leading designer and manufacturer of rapid diagnostic screening and testing products, has commenced clinical trials in the USA for its PIFA PLUSS Chlamydia Assay, the world’s first rapid test for Chlamydia diagnosis using a finger stick blood sample.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC